A double-blind pilot study of the effect of Prokarin™ on fatigue in multiple sclerosis

Abstract

In this 12-week study with 29 subjects, the effect of Prokarin™ (n=22), a proprietary blend of histamine and caffeine, was compared to placebo group (n=7) for the following outcomes: 1) fatigue as measured by the Modified Fatigue Impact Scale (MFIS); 2) lower limb function as measured by timed walk test; 3) upper limb function as measured by the pegboard test; 4) cognitive function as measured by the Paced Auditory Serial Additions Test (PASAT); 5) serum caffeine level; 6) change in brain chemistry as measured by quantitative magnetic resonance spectroscopy assay of N-acetyl aspartate (NAA); and 7) safety as measured by routine blood chemistry, TSH and urinalysis. Data were acquired at baseline, 4, 8 and 12 weeks. The Prokarin™ group MFIS mean was significantly different from the mean of the placebo group at 12 weeks (df=24, t=2.08, P=<0.02), with respective means of 37.40, SD=15.18, for the Prokarin™ group and 53.2, SD=11.39 for the controls. For the secondary endpoints (PASAT, 25 foot timed walk, peg test, and magnetic resonance spectroscopy [MRS]), there were no significant differences between the Prokarin™ -treated group and the placebo group. However, there were significant improvements within the Prokarin™ group for each of these measures for the pre-versus posttreatment comparison at 12 weeks. Serum caffeine data indicated that caffeine exerted no independent effect on performance. No laboratory abnormalities were seen, and the treatment was well tolerated. Conclusion: There was a modest-size statistical effect of Prokarin™ on fatigue in multiple sclerosis (MS) compared with the placebo group. A larger trial is warranted, based on this pilot study.

Keywords

clinical trial fatigue histamine multiple sclerosis

Get full access to this article

View all access options for this article.

References

Gillson G , Wright J , DeLack E , Ballasiotes G. Transdermal histamine in multiple sclerosis: Part Two. A proposed theoretical basis for its use . Alt Med Rev 2000; 5: 224-248 .

Gillson G , Wright J , DeLack E , Ballasiotes G. Transdermal histamine in multiple sclerosis: Part One. Clinical experience . Alt Med Rev 1999; 4: 424-428 .

Horton BT , Wagener HP , Aita J , Woltman HW. Treatment of multiple sclerosis by the intravenous administration of hista-mine . JAMA 1944; 124: 800-801 .

Horton BT. The clinical use of histamine . Postgrad Med 1951; 9: 1-23 .

Jonez HD. Management of multiple sclerosis . Postgrad Med 1952 May; 2: 15-22 .

King WP. The use of low-dose histamine therapy in otolaryngology . Ear Nose Throat J 1999; 78: 366-369 .

Fisk JD , Pontefract A , Ritvo PG , Archibald CJ , Murray TJ. The impact of fatigue on patients with multiple sclerosis . Can J Neurol Sci 1994; 21: 9-14 .

Minden S , Marder W , Harrold L , Dor A. Multiple Sclerosis: A Statistical Portrait. Cambridge: ABT Associates , 1993.

Sheean GL , Murray NM , Rothwell JC , Miller DH , Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis . Brain 1997; 120: 299-315 .

10.

Sahlin K. Metabolic factors in fatigue . Sports Med 1992; 13: 99-107 .

11.

Guidelines MSCfCP . Fatigue and multiple sclerosis. Washington, DC: Paralyzed Veterans of America , 1998, pp. 1-33.

12.

Rivto P , Fischer J , Miller D , Andrews H , Paty D , LaRocca N. Multiple Sclerosis Quality of Life Inventory: A User’s Manual. New York: National Multiple Sclerosis Society , 1997.

13.

Fischer JS , Rudick RA , Cutter GR , Reingold SC. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment . Mult Scler 1999; 5: 244-250 .

14.

Matthews PM , Pioro E , Narayanan S , et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy . Brain 1996; 119: 715-722 .

15.

Heide AC , Kraft GH , Slimp JC , et al. Cerebral N-acetyl aspartate is low in patients with multiple sclerosis and abnormal visual evoked potentials [see comments] . AJNR Am J Neuroradiol 1998; 19: 1047-1054 .

16.

Norberg HP , Schulak JA , Atlas B , Kaplan EL. Histamine-induced hypocalcemia in the rat . Metabolism 1976 Feb; 25: 131-134 .

17.

Posse S , Dager SR , Richards TL , et al. In vivo measurement of regional brain metabolic response to hyperventilation using Magnetic Resonance Proton Echo Planar Spectroscopic Imaging (PEPSI) . Mag Res Med 1997; 37: 858-865 .